董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Flemming Ornskov | 男 | Chairman of the Board | 66 | 48.04万美元 | 1.66 | 2024-04-12 |
| Udit Batra | 男 | President and CEO and Director | 53 | 874.22万美元 | 13.04 | 2024-04-12 |
| Linda Baddour | 女 | Independent Director | 65 | 33.49万美元 | 0.75 | 2024-04-12 |
| Mark Vergnano | 男 | Independent Director | 65 | 31.24万美元 | 0.49 | 2024-04-12 |
| Pearl S. Huang | -- | Independent Director | 66 | 32.24万美元 | 0.46 | 2024-04-12 |
| Wei Jiang | 女 | Independent Director | 60 | 30.79万美元 | 0.23 | 2024-04-12 |
| Dan Brennan | -- | Independent Director | 58 | 32.14万美元 | 0.17 | 2024-04-12 |
| Mark Vergnano | -- | Independent Director | 66 | 未披露 | 未持股 | 2024-04-12 |
| Richard Fearon | 男 | Independent Director | 68 | 25.60万美元 | 0.14 | 2024-04-12 |
| Christopher A. Kuebler | 男 | Independent Director | 70 | 32.89万美元 | 3.53 | 2024-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Udit Batra | 男 | President and CEO and Director | 53 | 874.22万美元 | 13.04 | 2024-04-12 |
| Amol Chaubal | 男 | Chief Financial Officer | 48 | 265.98万美元 | 2.81 | 2024-04-12 |
| Jianqing Bennett | 女 | Senior Vice President of TA Instruments Division | 54 | 210.88万美元 | 2.28 | 2024-04-12 |
董事简历
中英对照 | 中文 | 英文- Flemming Ornskov
-
Flemming Ornskov，2013年1月2日，他被任命为董事会成员，2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年，他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管；2008至2010年，担任Bausch & Lomb, Inc.的药物和非处方药全球总裁；2006年至2008年，先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官，2005至2006年，担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期，他就职于默克公司（Merck & Co., Inc.）和诺华制药（Novartis AG），在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学（University of Copenhagen）获得医学博士学位，在欧洲工商管理学院（INSEAD）获得工商管理学硕士学位并在哈佛大学（Harvard University）获得公共卫生硕士学位。
Flemming Ornskov,Chief Executive Officer and Board member, Shire plc (2013 – 2019);Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine, Bayer AG (2010 – 2012);Global President of Pharmaceuticals and OTC, Bausch & Lomb, Inc. (2008 – 2010);Held roles of increasing responsibility at among others, Merck & Co. Inc. and Novartis AG.MD, University of Copenhagen Medical School;MPH, Harvard University School of Public Health;MBA, INSEAD. - Flemming Ornskov，2013年1月2日，他被任命为董事会成员，2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年，他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管；2008至2010年，担任Bausch & Lomb, Inc.的药物和非处方药全球总裁；2006年至2008年，先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官，2005至2006年，担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期，他就职于默克公司（Merck & Co., Inc.）和诺华制药（Novartis AG），在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学（University of Copenhagen）获得医学博士学位，在欧洲工商管理学院（INSEAD）获得工商管理学硕士学位并在哈佛大学（Harvard University）获得公共卫生硕士学位。
- Flemming Ornskov,Chief Executive Officer and Board member, Shire plc (2013 – 2019);Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine, Bayer AG (2010 – 2012);Global President of Pharmaceuticals and OTC, Bausch & Lomb, Inc. (2008 – 2010);Held roles of increasing responsibility at among others, Merck & Co. Inc. and Novartis AG.MD, University of Copenhagen Medical School;MPH, Harvard University School of Public Health;MBA, INSEAD.
- Udit Batra
-
Udit Batra，2014年3月至2020年7月，默克公司（Merck KGaA）生命科学业务MilliporeSigma首席执行官Udit Batra。Merck KGaA消费者健康总裁兼首席执行官（2011年9月至2014年3月）。2006年至2011年，在诺华国际公司担任多种领导职务。麦肯锡公司（McKinsey & Company）高级业务经理（2001 - 2004）。默克公司研究员（1996 - 2001）。
Udit Batra,was appointed a Director of the Company as well as President and CEO on September 1, 2020. He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020. Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany's Consumer Health business. Dr. Batra oversaw the company's Bioethics Advisory Panel and had Board responsibility for the global Information Technology function. Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts. Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and non-profit sectors. Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer. - Udit Batra，2014年3月至2020年7月，默克公司（Merck KGaA）生命科学业务MilliporeSigma首席执行官Udit Batra。Merck KGaA消费者健康总裁兼首席执行官（2011年9月至2014年3月）。2006年至2011年，在诺华国际公司担任多种领导职务。麦肯锡公司（McKinsey & Company）高级业务经理（2001 - 2004）。默克公司研究员（1996 - 2001）。
- Udit Batra,was appointed a Director of the Company as well as President and CEO on September 1, 2020. He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020. Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany's Consumer Health business. Dr. Batra oversaw the company's Bioethics Advisory Panel and had Board responsibility for the global Information Technology function. Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts. Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and non-profit sectors. Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.
- Linda Baddour
-
Linda Baddour于2007年加入PRA，担任其执行副总裁兼首席财务官。加入PRA以前，从2002年到2007年，Baddour女士在PPD担任首席财务官，从1997年到2002年，担任首席会计官，从1995年到1997年，担任公司财务总管。Baddour女士在威明顿市的北卡罗来大学（University of North Carolina）获得工商管理硕士学位，她还是一位注册会计师。
Linda Baddour,Chief Financial Officer and Accounting Officer (2002 – 2007), Chief Accounting Officer (1997 – 2007); Corporate Controller (1995 – 1997), Pharmaceutical Product Development, Inc.;Controller, Cooperative Bank for Savings Inc. (1980 – 1995).BA and MBA, University of North Carolina at Wilmington;Certified Public Accountant. - Linda Baddour于2007年加入PRA，担任其执行副总裁兼首席财务官。加入PRA以前，从2002年到2007年，Baddour女士在PPD担任首席财务官，从1997年到2002年，担任首席会计官，从1995年到1997年，担任公司财务总管。Baddour女士在威明顿市的北卡罗来大学（University of North Carolina）获得工商管理硕士学位，她还是一位注册会计师。
- Linda Baddour,Chief Financial Officer and Accounting Officer (2002 – 2007), Chief Accounting Officer (1997 – 2007); Corporate Controller (1995 – 1997), Pharmaceutical Product Development, Inc.;Controller, Cooperative Bank for Savings Inc. (1980 – 1995).BA and MBA, University of North Carolina at Wilmington;Certified Public Accountant.
- Mark Vergnano
-
Mark Vergnano是科慕公司的董事长兼董事，科慕公司是钛技术、氟产品和化学解决方案的生产商。此前，Vergnano先生于2015年7月至2021年7月担任The Chemours Company总裁兼首席执行官。2009年至2015年6月，他担任E. I. du Pont de Nemours公司执行副总裁。在杜邦的时候，他曾于2006年至2009年担任安全与防护集团副总裁，于2005年至2006年担任杜邦表面与建筑创新公司副总裁兼总经理，于2003年至2005年担任杜邦无纺布公司副总裁兼总经理。Vergnano先生于1980年加入杜邦公司，担任工艺工程师并在杜邦公司的多个全球地点担任各种制造、技术和管理任务。Vergnano先生是国家安全委员会和美国化学委员会董事会的前任主席。
Mark Vergnano, served as the Chairman of the Board of The Chemours Company, a titanium technologies, fluoroproducts, and chemical solutions producer, from July 2021 until his retirement in April 2022. Previously, Vergnano served as the President and Chief Executive Officer of Chemours from July 2015 to July 2021. He served as Executive Vice President, E. I. du Pont de Nemours and Company from 2009 to June 2015. While at DuPont, he served as Group Vice President—Safety & Protection from 2006 to 2009, Vice President and General Manager—DuPont Surfaces and Building Innovations from 2005 to 2006 and Vice President and General Manager—DuPont Nonwovens from 2003 to 2005.Mr. Vergnano joined DuPont in 1980 as a process engineer and held a variety of manufacturing, technical and management assignments throughout multiple global locations in DuPont's organization. Mr. Vergnano is currently a director of Waters Corporation, a specialty measurement company. Mr. Vergnano is a former Chairman of the Board of Directors for both the National Safety Council, and the American Chemistry Council. He is the founding chair of the Future of Stem Scholars Initiative and the Vergnano Institute for Inclusion at the University of Connecticut. - Mark Vergnano是科慕公司的董事长兼董事，科慕公司是钛技术、氟产品和化学解决方案的生产商。此前，Vergnano先生于2015年7月至2021年7月担任The Chemours Company总裁兼首席执行官。2009年至2015年6月，他担任E. I. du Pont de Nemours公司执行副总裁。在杜邦的时候，他曾于2006年至2009年担任安全与防护集团副总裁，于2005年至2006年担任杜邦表面与建筑创新公司副总裁兼总经理，于2003年至2005年担任杜邦无纺布公司副总裁兼总经理。Vergnano先生于1980年加入杜邦公司，担任工艺工程师并在杜邦公司的多个全球地点担任各种制造、技术和管理任务。Vergnano先生是国家安全委员会和美国化学委员会董事会的前任主席。
- Mark Vergnano, served as the Chairman of the Board of The Chemours Company, a titanium technologies, fluoroproducts, and chemical solutions producer, from July 2021 until his retirement in April 2022. Previously, Vergnano served as the President and Chief Executive Officer of Chemours from July 2015 to July 2021. He served as Executive Vice President, E. I. du Pont de Nemours and Company from 2009 to June 2015. While at DuPont, he served as Group Vice President—Safety & Protection from 2006 to 2009, Vice President and General Manager—DuPont Surfaces and Building Innovations from 2005 to 2006 and Vice President and General Manager—DuPont Nonwovens from 2003 to 2005.Mr. Vergnano joined DuPont in 1980 as a process engineer and held a variety of manufacturing, technical and management assignments throughout multiple global locations in DuPont's organization. Mr. Vergnano is currently a director of Waters Corporation, a specialty measurement company. Mr. Vergnano is a former Chairman of the Board of Directors for both the National Safety Council, and the American Chemistry Council. He is the founding chair of the Future of Stem Scholars Initiative and the Vergnano Institute for Inclusion at the University of Connecticut.
- Pearl S. Huang
-
Pearl S. Huang, Cygnal Therapeutics总裁兼首席执行官，2019年1月至现在。旗舰先锋创投合伙人（2019年1月至今）。高级副总裁兼全球治疗模式主管。F. Hoffman La-Roche, Ltd.（2014年12月至2018年12月）。葛兰素史克公司（GlaxoSmithKline plc， 2012-2014）副总裁兼发现学术伙伴（DPAc）替代发现和开发（Alternative Discovery and Development）全球主管。2010-2012年，Beigene LTD的创始人和首席执行官。2006-2010年，担任默克公司（Merck and Co.）肿瘤整合、发现和早期开发副总裁。曾在Merck & Co.， GlaxoSmithKline, Bristol Myers Squibb等公司担任越来越多的职务。
Pearl S. Huang,Chief Executive Officer, Cygnal Therapeutics (2019 – 2022);Venture Partner, Flagship Pioneering (2019 – 2022);Senior Vice President and Global Head, Therapeutic Modalities, F. Hoffman La-Roche, Ltd. (2014 – 2018);Vice President and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, GlaxoSmithKline plc (2012 – 2014);Founder and CSO, Beigene LTD (2010 – 2012);Vice President, Oncology Integrator, Discovery and Early Development, Merck and Co. (2006 – 2010);Held roles of increasing responsibility at Merck & Co. Inc. and GlaxoSmithKline plc.BS, Biology, MIT;Ph.D., Molecular Biology, Princeton University. - Pearl S. Huang, Cygnal Therapeutics总裁兼首席执行官，2019年1月至现在。旗舰先锋创投合伙人（2019年1月至今）。高级副总裁兼全球治疗模式主管。F. Hoffman La-Roche, Ltd.（2014年12月至2018年12月）。葛兰素史克公司（GlaxoSmithKline plc， 2012-2014）副总裁兼发现学术伙伴（DPAc）替代发现和开发（Alternative Discovery and Development）全球主管。2010-2012年，Beigene LTD的创始人和首席执行官。2006-2010年，担任默克公司（Merck and Co.）肿瘤整合、发现和早期开发副总裁。曾在Merck & Co.， GlaxoSmithKline, Bristol Myers Squibb等公司担任越来越多的职务。
- Pearl S. Huang,Chief Executive Officer, Cygnal Therapeutics (2019 – 2022);Venture Partner, Flagship Pioneering (2019 – 2022);Senior Vice President and Global Head, Therapeutic Modalities, F. Hoffman La-Roche, Ltd. (2014 – 2018);Vice President and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, GlaxoSmithKline plc (2012 – 2014);Founder and CSO, Beigene LTD (2010 – 2012);Vice President, Oncology Integrator, Discovery and Early Development, Merck and Co. (2006 – 2010);Held roles of increasing responsibility at Merck & Co. Inc. and GlaxoSmithKline plc.BS, Biology, MIT;Ph.D., Molecular Biology, Princeton University.
- Wei Jiang
-
Wei Jiang 拜耳制药中国及亚太区执行副总裁兼总裁，拜耳集团大中华区总裁 2015 年至今，阿斯利康公司 GRA 事业部和大客户部高级副总裁（2011-2012 年及其他管理职务（2006 年） -2010），Guidant Corporation 中国业务董事总经理 （2004-2006），在 Eli Lilly & Company 担任各种管理职务 （1999-2004）。
Wei Jiang,Former EVP, President of Pharmaceuticals Region China &Asia Pacific (2015 – 2021), and President of Bayer Group Greater China Region (2019 – 2021), Bayer AG;Senior Vice President, GRA BU & Key Accounts (2011 – 2012), held other management roles (2006 – 2010), AstraZeneca plc;Managing Director, China Operations (2004 – 2006), Guidant Corporation;Various management roles, Eli Lilly & Company (1999 – 2004).BBA, Campbell University;MA, Economics and Finance, Indiana State University. - Wei Jiang 拜耳制药中国及亚太区执行副总裁兼总裁，拜耳集团大中华区总裁 2015 年至今，阿斯利康公司 GRA 事业部和大客户部高级副总裁（2011-2012 年及其他管理职务（2006 年） -2010），Guidant Corporation 中国业务董事总经理 （2004-2006），在 Eli Lilly & Company 担任各种管理职务 （1999-2004）。
- Wei Jiang,Former EVP, President of Pharmaceuticals Region China &Asia Pacific (2015 – 2021), and President of Bayer Group Greater China Region (2019 – 2021), Bayer AG;Senior Vice President, GRA BU & Key Accounts (2011 – 2012), held other management roles (2006 – 2010), AstraZeneca plc;Managing Director, China Operations (2004 – 2006), Guidant Corporation;Various management roles, Eli Lilly & Company (1999 – 2004).BBA, Campbell University;MA, Economics and Finance, Indiana State University.
- Dan Brennan
-
Dan Brennan，高级副总裁兼公司财务总监，（2010 – 2013）；在财务职能内担任增加责任的各种角色（1996 – 2009），波士顿科学国际有限公司；在财务职能内担任增加责任的角色，Millipore Corporation（1990 – 1996）；公司审计师，Standex，Inc.（1988 – 1989），巴布森学院BS和MBA；注册会计师。
Dan Brennan,Senior Vice President and Corporate Controller, (2010 – 2013); Various roles of increasing responsibility within finance function (1996 – 2009), Boston Scientific Corporation;Held roles of increasing responsibility within finance function, Millipore Corporation (1990 – 1996);Corporate Auditor, Standex, Inc. (1988 – 1989).BS and MBA, Babson College;Certified Public Accountant. - Dan Brennan，高级副总裁兼公司财务总监，（2010 – 2013）；在财务职能内担任增加责任的各种角色（1996 – 2009），波士顿科学国际有限公司；在财务职能内担任增加责任的角色，Millipore Corporation（1990 – 1996）；公司审计师，Standex，Inc.（1988 – 1989），巴布森学院BS和MBA；注册会计师。
- Dan Brennan,Senior Vice President and Corporate Controller, (2010 – 2013); Various roles of increasing responsibility within finance function (1996 – 2009), Boston Scientific Corporation;Held roles of increasing responsibility within finance function, Millipore Corporation (1990 – 1996);Corporate Auditor, Standex, Inc. (1988 – 1989).BS and MBA, Babson College;Certified Public Accountant.
- Mark Vergnano
-
Mark Vergnano，角色的责任越来越大，包括Chemours（2015 – 2021）董事长（2021）；总裁兼首席执行官（2015 – 2021）。杜邦（1980 – 2015）执行副总裁（2009 – 2015）；集团安全和保护副总裁（2006 – 2009），非织造布和建筑创新副总裁/总经理（2002 – 2006）。康乃狄克州大学学士；弗吉尼亚联邦大学MBA。
Mark Vergnano,Roles of increasing responsibility, including Chemours (2015 – 2021) Chairman (2021); President and CEO (2015 – 2021). DuPont (1980 – 2015) Executive Vice President (2009 – 2015); Group Vice President, Safety and Protection (2006 – 2009), Vice President/General Manager, Nonwovens and Building Innovations (2002 – 2006).BS, University of Connecticut;MBA, Virginia Commonwealth University. - Mark Vergnano，角色的责任越来越大，包括Chemours（2015 – 2021）董事长（2021）；总裁兼首席执行官（2015 – 2021）。杜邦（1980 – 2015）执行副总裁（2009 – 2015）；集团安全和保护副总裁（2006 – 2009），非织造布和建筑创新副总裁/总经理（2002 – 2006）。康乃狄克州大学学士；弗吉尼亚联邦大学MBA。
- Mark Vergnano,Roles of increasing responsibility, including Chemours (2015 – 2021) Chairman (2021); President and CEO (2015 – 2021). DuPont (1980 – 2015) Executive Vice President (2009 – 2015); Group Vice President, Safety and Protection (2006 – 2009), Vice President/General Manager, Nonwovens and Building Innovations (2002 – 2006).BS, University of Connecticut;MBA, Virginia Commonwealth University.
- Richard Fearon
-
Richard Fearon，副董事长（2009年至2021年）；Eaton公司首席财务和规划官（2002年至2021年）；企业发展和战略规划高级副总裁（1997年至2001年）；1995年至1997年，Transamerica公司企业发展副总裁；1990年至1995年，NatSteel化学公司副董事长和NatSteel有限公司企业发展总经理。Fearon在斯坦福大学获得学士学位，在哈佛大学获得法学博士和工商管理硕士学位。
Richard Fearon,Non-Executive Chairman of the Board (Dec. 2023 – present), Avient Corporation (NYSE: AVNT);Vice Chairman (2009 – 2021); Chief Financial and Planning Officer (2002 – 2021), Eaton Corporation;Senior Vice President, Corporate Development and Strategic Planning (1997 – 2001); Vice President, Corporate Development (1995 – 1997), Transamerica Corporation;Vice Chairman, NatSteel Chemicals and General Manager, Corporate Development (1990 – 1995), NatSteel Ltd.;Held positions at Booz Allen Hamilton, The Walt Disney Company, and The Boston Consulting Group.AB, Stanford University;JD and MBA, Harvard University. - Richard Fearon，副董事长（2009年至2021年）；Eaton公司首席财务和规划官（2002年至2021年）；企业发展和战略规划高级副总裁（1997年至2001年）；1995年至1997年，Transamerica公司企业发展副总裁；1990年至1995年，NatSteel化学公司副董事长和NatSteel有限公司企业发展总经理。Fearon在斯坦福大学获得学士学位，在哈佛大学获得法学博士和工商管理硕士学位。
- Richard Fearon,Non-Executive Chairman of the Board (Dec. 2023 – present), Avient Corporation (NYSE: AVNT);Vice Chairman (2009 – 2021); Chief Financial and Planning Officer (2002 – 2021), Eaton Corporation;Senior Vice President, Corporate Development and Strategic Planning (1997 – 2001); Vice President, Corporate Development (1995 – 1997), Transamerica Corporation;Vice Chairman, NatSteel Chemicals and General Manager, Corporate Development (1990 – 1995), NatSteel Ltd.;Held positions at Booz Allen Hamilton, The Walt Disney Company, and The Boston Consulting Group.AB, Stanford University;JD and MBA, Harvard University.
- Christopher A. Kuebler
-
Christopher A. Kuebler，2001年12月他担任公司董事。他现在也在Waters公司董事会任职，Waters是一家分析技术服务公司。1997年1月至2005年12月， 他担任Covance 公司董事会主席，Covance是一家药物开发服务公司。1994年11月至2004年12月，他担任CEO。1993年3月至1994年11月担任雅培公司欧洲运营副总裁，雅培是一家多样化健康保健公司。1986年1月至1993年3月， 他在雅培制药部担任过很多职位，曾担任部门副总裁，在这之前他负责欧洲市场营销。他也曾在Squibb公司和Monsanto医疗保健公司任职。他拥有加州大学生物科学学士学位。
Christopher A. Kuebler,Chairman and Chief Executive Officer (1994 – 2004), Chairman (during 2005), Covance Inc. and its predecessor companie;Spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc., and the Monsanto Company.BS, Biology, Florida State University. - Christopher A. Kuebler，2001年12月他担任公司董事。他现在也在Waters公司董事会任职，Waters是一家分析技术服务公司。1997年1月至2005年12月， 他担任Covance 公司董事会主席，Covance是一家药物开发服务公司。1994年11月至2004年12月，他担任CEO。1993年3月至1994年11月担任雅培公司欧洲运营副总裁，雅培是一家多样化健康保健公司。1986年1月至1993年3月， 他在雅培制药部担任过很多职位，曾担任部门副总裁，在这之前他负责欧洲市场营销。他也曾在Squibb公司和Monsanto医疗保健公司任职。他拥有加州大学生物科学学士学位。
- Christopher A. Kuebler,Chairman and Chief Executive Officer (1994 – 2004), Chairman (during 2005), Covance Inc. and its predecessor companie;Spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc., and the Monsanto Company.BS, Biology, Florida State University.
高管简历
中英对照 | 中文 | 英文- Udit Batra
Udit Batra，2014年3月至2020年7月，默克公司（Merck KGaA）生命科学业务MilliporeSigma首席执行官Udit Batra。Merck KGaA消费者健康总裁兼首席执行官（2011年9月至2014年3月）。2006年至2011年，在诺华国际公司担任多种领导职务。麦肯锡公司（McKinsey & Company）高级业务经理（2001 - 2004）。默克公司研究员（1996 - 2001）。
Udit Batra,was appointed a Director of the Company as well as President and CEO on September 1, 2020. He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020. Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany's Consumer Health business. Dr. Batra oversaw the company's Bioethics Advisory Panel and had Board responsibility for the global Information Technology function. Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts. Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and non-profit sectors. Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.- Udit Batra，2014年3月至2020年7月，默克公司（Merck KGaA）生命科学业务MilliporeSigma首席执行官Udit Batra。Merck KGaA消费者健康总裁兼首席执行官（2011年9月至2014年3月）。2006年至2011年，在诺华国际公司担任多种领导职务。麦肯锡公司（McKinsey & Company）高级业务经理（2001 - 2004）。默克公司研究员（1996 - 2001）。
- Udit Batra,was appointed a Director of the Company as well as President and CEO on September 1, 2020. He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020. Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany's Consumer Health business. Dr. Batra oversaw the company's Bioethics Advisory Panel and had Board responsibility for the global Information Technology function. Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts. Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and non-profit sectors. Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.
- Amol Chaubal
Amol Chaubal于5月12日被任命为沃特世公司首席财务官。此前，Chaubal曾担任生命科学公司Quanterix Corporation的首席财务官，自2019年4月起担任首席财务官。在Quanterix之前，Chaubal先生于2017年10月至2019年4月担任全球医疗器械公司Smith&Nephew的全球运营首席财务官。在施乐辉任职之前，他曾于2015年7月至2017年10月担任帕雷塞尔临床研究服务和接入业务的公司副总裁兼财务总监。
Amol Chaubal,was appointed Chief Financial Officer of Waters Corporation on May 12, 2021. Previously, Mr. Chaubal was Chief Financial Officer of Quanterix Corporation, a life sciences company, where he served as Chief Financial Officer since April 2019. Before Quanterix, Mr. Chaubal served as Chief Financial Officer, Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019. Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services and Access business at Parexel from July 2015 to October 2017.- Amol Chaubal于5月12日被任命为沃特世公司首席财务官。此前，Chaubal曾担任生命科学公司Quanterix Corporation的首席财务官，自2019年4月起担任首席财务官。在Quanterix之前，Chaubal先生于2017年10月至2019年4月担任全球医疗器械公司Smith&Nephew的全球运营首席财务官。在施乐辉任职之前，他曾于2015年7月至2017年10月担任帕雷塞尔临床研究服务和接入业务的公司副总裁兼财务总监。
- Amol Chaubal,was appointed Chief Financial Officer of Waters Corporation on May 12, 2021. Previously, Mr. Chaubal was Chief Financial Officer of Quanterix Corporation, a life sciences company, where he served as Chief Financial Officer since April 2019. Before Quanterix, Mr. Chaubal served as Chief Financial Officer, Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019. Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services and Access business at Parexel from July 2015 to October 2017.
- Jianqing Bennett
Jianqing Bennett于2021年5月1日被任命为TA仪表部高级副总裁。此前，Bennett女士担任高级副总裁，高增长市场在贝克曼库尔特诊断从2017年11月至2021年3月。在此之前，从2007年到2017年，她曾在Carestream Health Inc担任过多个高级管理职位，包括从2015年8月到2017年11月担任医疗数字解决方案总裁。
Jianqing Bennett,was appointed Senior Vice President of TA Instruments Division on May 1, 2021. Previously, Ms. Bennett served as Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics from November 2017 to March 2021. Prior to that, from 2007-2017, she held various senior management positions at Carestream Health Inc, including serving as President, Medical Digital Solutions from August 2015 to November 2017.- Jianqing Bennett于2021年5月1日被任命为TA仪表部高级副总裁。此前，Bennett女士担任高级副总裁，高增长市场在贝克曼库尔特诊断从2017年11月至2021年3月。在此之前，从2007年到2017年，她曾在Carestream Health Inc担任过多个高级管理职位，包括从2015年8月到2017年11月担任医疗数字解决方案总裁。
- Jianqing Bennett,was appointed Senior Vice President of TA Instruments Division on May 1, 2021. Previously, Ms. Bennett served as Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics from November 2017 to March 2021. Prior to that, from 2007-2017, she held various senior management positions at Carestream Health Inc, including serving as President, Medical Digital Solutions from August 2015 to November 2017.